With the rapid and ongoing global growth of cell and gene (C&G) products, there is an opportunity for Australia to be a regional C&G hub. This report was commissioned by AusBiotech and delivered by Biointelect to build on 2021’s Regenerative Medicines Consortium Programme and produce a National Blueprint for the strategic growth and development of an Australian C&G manufacturing ecosystem. Key recommendations from this project include fostering a skilled local workforce, streamlining market access and patient delivery, and strategically expanding our translational and commercial capabilities to meet the increasing demands of the global market.